These findings suggest that the ALMS1‐IT1‐STAT3 axis represents a novel therapeutic target in CRC, providing insights into potential interventions aimed at disrupting this pathway to inhibit tumour progression and improve patient outcomes. This evidence concerns the gene ALMS1 and neoplasm.